Back to Search
Start Over
Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report
- Source :
- The Laryngoscope. 130:907-910
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- In head and neck squamous cell carcinoma, immune checkpoint inhibitors (ICI) lead to improved outcomes. There has been reports of accelerated disease progression, or hyperprogression, after ICI initiation. We present a case of hyperprogression after one dose of nivolumab in maxillary sinus squamous cell carcinoma. The patient had complete vision loss due to disease progression into the orbit, as well as intracranial invasion, lytic metastases, and new widespread distal metastases. Hyperprogression can occur after the first dose of immunotherapy. Absent biomarkers regarding individual risk of hyperprogression, caution should be exercised in using ICI in sinonasal cancers with orbital abutting disease. Laryngoscope, 130:907-910, 2020.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
business.industry
Immune checkpoint inhibitors
medicine.medical_treatment
Head and neck cancer
Immunotherapy
Disease
Sinonasal cancer
medicine.disease
Head and neck squamous-cell carcinoma
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Otorhinolaryngology
030220 oncology & carcinogenesis
Internal medicine
medicine
Maxillary Sinus Squamous Cell Carcinoma
Nivolumab
business
Subjects
Details
- ISSN :
- 15314995 and 0023852X
- Volume :
- 130
- Database :
- OpenAIRE
- Journal :
- The Laryngoscope
- Accession number :
- edsair.doi...........e0f7041a12e091b644700a6a2c77ddab